Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linagliptin + pioglitazone
- Development stage
- Phase 3
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Linagliptin + pioglitazone is a fixed-dose oral combination of two antihyperglycemic agents developed for the treatment of type 2 diabetes mellitus. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), enhancing insulin secretion and reducing glucagon release in a glucose-dependent manner. Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity in adipose tissue, muscle, and liver. The combination targets complementary pathophysiological mechanisms in type 2 diabetes to improve glycemic control[1][3][4][6].
- Brand names
- Trazenta
- Other names
- linagliptin/pioglitazonepioglitazone/linagliptin
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on linagliptin + pioglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linagliptin + pioglitazone.